## SUPPLEMENTARY TABLES

**Supplementary Table 1**. The number of lipid species identified in positive and negative ion MS modes using 4 different lipid extractions of a mouse brain.

Extraction Method	# Lipid species (positive mode)	# Lipid species (negative mode)	# Lipid species (both modes)	
Folch	232	129	361	
Folch - HCl	316	189	505	
Bligh Dyer	362	222	584	
Bligh Dyer - HCI	497	324	821	

**Supplementary Table 2**. Results from untargeted LC-MS analyses (ddMS2) to identify lipids that were significantly altered upon overexpression of recombinant DGK $\varepsilon$  in HEK293T cells (*n*=5 biological samples). Significantly altered lipids were identified by a Q-value < 0.05 following a Benjamini-Hochberg correction of a two-sided binomial test. Data shown are representative of two experiments (*n*=2 biologically independent experiments).

Lipid ID	Log <sub>2</sub> Fold Change	Q Value
PG(18:1/14:0)	2.03	0.0001
TG(18:1/18:1/20:4)	-2.38	0.0002
PI(16:0_20:4)	1.89	0.0003
PG(16:1/18:1)	-1.15	0.0003
PE(18:1/20:4)	-0.47	0.0006
PS(16:0/20:4)	-3.07	0.0015
PG(18:1/18:1)	-0.68	0.0037
PE(16:1/18:1)	-0.26	0.0146
PE(18:2/22:6)	-0.31	0.0161
PG(18:0/18:1)	-0.26	0.0247
PG(18:1/20:4)	0.97	0.039
PC(18:0/18:1)	-0.27	0.041
PC(18:1/18:1)	-0.33	0.041
PE(16:1/22:6)	-0.38	0.041
PI(18:0/22:6)	2.12	0.041
PS(18:0/22:4)	-0.56	0.041
SM(d16:1/18:1)	-0.39	0.041
PE(16:1/16:1)	-0.34	0.0418
SM(d18:0/18:1)	-0.36	0.0418
PA(16:0/16:0)	1.33	0.0058

**Supplementary Table 3**. DAG lipids with cellular levels that were reduced upon recombinant overexpression of DGK $\alpha$  in HEK293T cells (*n*=5 biological samples). The fatty acid composition of lipids shown match DAG species identified as substrates of endogenous DGK $\alpha$  in A549 shRNA-mediated knockdown studies (Supplementary Fig. 14). Data shown are representative of two experiments (*n*=2 biologically independent experiments).

Lipid ID	Log <sub>2</sub> Fold Change
C18:0_18:0 DAG	-0.17
C18:1_20:1 DAG	-0.21
C16:0_22:1 DAG	-0.20
C16:1_18:1 DAG	-0.19
C16:0_20:1 DAG	-0.25

## SUPPLEMENTARY FIGURES



**Supplementary Figure 1. The diacylglycerol kinase superfamily regulates cell signaling via metabolism of lipid messengers**. Classification of the 10 mammalian DGK isoforms into 5 subtypes based on structural motifs. RVH: recoverin homology domain; EF: EF Hand motif; C1: atypical/typical C1 domain; PH: pleckstrin homology domain; SAM: sterile alpha motif; EPAP: Glu-Pro-Ala-Pro repeats; PDZ: protein-protein interactions; HD: hydrophobic domain; MARCKS: myristoylated alanine rich protein kinase C substrate domain; ANK: Ankyrin repeats; PR: proline-rich region.

### DGK Structural Superfamily



Supplementary Figure 2. Metabolomics platform for quantitative evaluation of the DGK-regulated lipidome. Evaluation of DGK metabolic activity in live cells was achieved by: (1) recombinant overexpression of individual DGK isoforms via transient transfection. (2) Lipid extraction using a modified Bligh Dyer method. (3) Quantitative analysis of cellular lipids using tandem LC-MS/MS for the separation of lipids and subsequent detection of MS1 precursor ions and MS2 fragment ions. (4) Lipid identification using LipidSearch<sup>™</sup>, which matched MS1 and MS2 ions with library spectra, followed by quantitation of lipid abundance by peak area. Diagnostic ions (i.e. loss of fatty acid chains) were used to distinguish closely related lipid species. (5) Parallel-reaction monitoring (PRM) for targeted quantitation of changes in low abundance and/or co-eluting lipid species. (6) Top10 data-dependent method (i.e. ddMS2) to acquire MS2 spectra for the 10 most abundant ions from each MS1 scan event for discovery-based, global lipidome profiling. Mock data shown in workflow (5, 6) are representative of analyses performed using LC-MS/MS.



Supplementary Figure 3. Time-course of recombinant overexpression of mammalian DGK isoforms in HEK293T cells. Western blots showing the expression of a representative human DGK isoform from each subtype over a 48-hour time course after transient transfection. Recombinant DGKs were detected using anti-FLAG (DGK $\alpha$ , DGK $\kappa$ , DGK $\varepsilon$ , DGK $\theta$ ) or anti-HA (DGK $\zeta$ 2) antibodies. Soluble fractions are shown for DGKs except for DGK $\varepsilon$ , which is expressed in the membrane fraction. Full blot image is shown in Supplementary Fig. 25. Data shown are representative of two experiments (*n*=2 biologically independent experiments).



Supplementary Figure 4. Recombinant overexpression of DGK isoforms had negligible effects on expression levels of endogenous DGKa. Western blot showing expression levels of endogenous DGKa were not changed upon overexpression of individual recombinant human DGK isoforms in HEK293T cells over a 48-hour time course. The molecular weight (MW) of endogenous DGKa (red) matched the MW of recombinant DGKa (blue) using a polyclonal anti-DGKa antibody. The bottom panel is the same blot with enhanced contrast to highlight the endogenous DGKa band. Full blot image is shown in Supplementary Fig. 26. Data shown are representative of two experiments (n=2 biologically independent experiments).



Supplementary Figure 5. Example of a manual verification to confirm lipid ion identification by LipidSearch<sup>TM</sup> software. Lipids are identified by matching experimental MS2 spectra with in-silico spectra found in a curated database to enable identification of different classes of lipid species. The MS2 spectra are matched to precursor MS1 peaks. The MS1 area under the peak from select sample analyses can be superimposed to enable comparison of lipid levels in different samples (e.g. mock- versus DGK $\alpha$ -transfected HEK293T cells). High confidence lipid identifications can be obtained in LipidSearch<sup>TM</sup> through stringent stipulations of several lipid analyte detection and database match criteria: retention time, observed adduct m/z, delta ppm (mass accuracy), peak quality, signal-to-noise, ID quality, and fragment ion intensity ratios. An example MS2 spectrum is shown with annotated fragment ions typically observed in positive ion analysis of a lipid ammonium adduct ion, including loss of the hydroxyl group from precursor ion (M-OH), fragment ion resulting from the neutral loss of fatty acyl chains and ammonia (NL[FA]-H+NH4), loss of hydroxyl group from the released fatty acyl chain (FA-OH), and multiple methylene (CH<sub>2</sub>) loss fragmentations of these charged fatty acyl chains.



**Supplementary Figure 6. HCD-induced fragmentation of ammoniated glycerolipid products.** Fragmentation spectra produced by loss of ammonia and a *sn*-1 or *sn*-2 fatty acid of an ammoniated diacylglycerol (DAG) precursor ion are shown with proposed fragmentation mechanisms (red and blue peaks). All subsequent DAG identifications were confirmed by the fragment ions that resulted from the losses of both fatty acid chains from the ammoniated precursor ion.



Supplementary Figure 7. Expression of mammalian DGK isoforms in HEK293T cells. Western blots showing recombinant overexpression of the 10 human DGK isoforms. Western blot data showed comparable expression of recombinant DGKs across 5 biological samples. All recombinant DGKs were detected using anti-FLAG antibody with the exception of DGK $\zeta$ 2 and DGK1, which were detected via an anti-HA antibody; "M" represents mock lane. All data shown are for soluble proteomes with the exception of recombinant DGK $\epsilon$ , which is expressed in membrane fractions. Full blot image is shown in Supplementary Fig. 27. All data shown are representative of four experiments (*n*=4 biologically independent experiments).



**Supplementary Figure 8**. Hierarchical clustering of DAG lipidome data from Fig. 2a shows relationships between DGK isoforms with regards to the magnitude of changes in detected DAGs.



**Supplementary Figure 9**. Hierarchical clustering of DAG lipidome data from Fig. 2a shows the relationship for metabolism by individual isoforms (DGK $\alpha$ , green cluster), their fatty acyl chain composition (orange and blue clusters), or through a combination of these two relationships (red cluster).



# DGK Superfamily Targeted Analysis

Supplementary Figure 10. Phosphatidic acid (PA) metabolic profiles of the DGK superfamily. Heat map displaying the  $log_2$  fold change in cellular PA lipid levels in HEK293T cells expressing individual recombinant human DGK isoforms compared with non-transfected (mock) controls (n=5 biological samples). Data shown are representative of two experiments (n=2 biologically independent experiments).



Supplementary Figure 11. Direct DAG to PA conversion in live cells expressing recombinant DGK isoforms. Heat maps showing DAG and PA lipids with matching fatty acyl chain composition that are decreased (blue cell) and increased (red cell), respectively, upon overexpression of recombinant human DGKs. These data support a direct DGK-mediated phosphorylation of DAG substrate to produce the corresponding PA product for the lipid compositions and DGK isoforms shown (n=5 biological samples). Data shown are representative of two experiments (n=2 biologically independent experiments).

### C1A Domain

CLUSTAL O(1.2.4) multiple se	quence alignment		
DGKaC1A P51556 203-251	HHIWRPKRFSRPVYCNLCI	EL-SIGLGK <mark>QGLSCNLCKYIVHDHCAMK</mark> AQPC- NMLTGVGKOGLCCSECKYTVHERCARAP-PSC	251 292
DGKgC1A P49620 268-318	RHAWTLKHFKKPTYCNFC	IIMLMGVRKQGLCCIYCKYAVHQRCVSNSIPGC	318
# Percent Identity Matrix	- created by Clusta	12.1	
1: DGKaC1A P51556 203-2	51 100.00 60.42	46.94	
2: DGKbC1A P49621 243-2	92 60.42 100.00	62.00	
3: DGKgC1A P49620 268-3	18 46.94 62.00	100.00	

### C1B Domain

CLUSTAL 0(1.2.4) multiple sequence alignment

DGKaC1B P51556 267-317 DGKbC1B P49621 307-356 DGKgC1B P49620 333-380	PHVWVRGGCHSGRCDRCQK HHYWVEGNC-PTKCDKCHK QHAWVEGNS-SVKCDRCHK * **.* :**:*:*	KIRTYHSLTGLHCVWCHLEIHDDCLQAVGPI TVKCYQGLTGLHCVWCQTTLHN KCASHLKPI SIKCYQSVTAR HCVWCRMTFHRKCELSTA- **. *****: :* .*	EC 317 EC 356 -C 380 *
# Percent Identity Matrix	<ul> <li>created by Clusta</li> </ul>	12.1	
1: DGKaC1B P51556 267-3 2: DGKbC1B P49621 307-3	17 100.00 48.00 56 48.00 100.00	45.83 56.25	
3: DGKgC1B P49620 333-3	80 45.83 56.25	100.00	

#### **Catalytic Domain**

CLUSTAL 0(1.2.4) multiple sequence alignment

DGKaC P51556 365-498 DGKbC P49621 431-565 DGKgC P49620 427-561	SNTHPLLVFINPKSGGKQGQSVLwKFQYILNPRQVFNLK-DGPEPGLRFFKDVPQFRVLV         423           PGTHPLLVFNPKSGGKQGERIYRKFQYLLNPRQVFSLLSGNGPMPGLHFFRDVPDFRVLA         496           PGTHPLLVVFNPKSGGRQGERIYRKFQVLKNPKQVFNLKGGPTGLNFFQDTPDFRVLA         486					
DGKaC P51556 365-498 DGKbC P49621 431-565 DGKgC P49620 427-561	CGGDGTVGWILETIDKANFPIVPPVAVLPLGTGNDLARCLRWGRGYEGENLRKILKDIEI 48: CGGDGTVGWILDCIEKANVVKHPPVATLPLGTGNDLARCLRWGGGYEGENLMKILKDIES 55: CGGDGTVGWILDCIDKANFTKHPPVAVLPLGTGNDLARCLRWGGYEGGSLTKILKEIEQ 54:					
DGKaC P51556 365-498 DGKbC P49621 431-565 DGKgC P49620 427-561 # Percent Identity Matri	SKVVYLDRWLLEVIP 498 STEIMLDRWKFEVTP 565 SPLVMLDRWYLEVMP 561 * :**** x - created by Clustal2.1					
1: DGKaC P51556 365-4 2: DGKbC P49621 431-5 3: DGKgC P49620 427-5	98 100.00 73.13 73.13 65 73.13 100.00 77.78 61 73.13 77.78 100.00					
Accessory Domain						

CLUSTAL O(1.2.4) multiple sequence alignment

DGKaA P51556 512-693 DGKbA P49621 579-759 DGKgA P49620 575-749	QIINNYFSIGVDASIAHRFHLMREK <mark>YPEKFNSR</mark> MKNKLWYLEFATSESIFSTCKKLEESV -IINWYFSIGVDASIAHRFHIMREK <mark>HPEKFNSR</mark> MKNKFWYFEFGTSETFSATCKKLHESV -IMMNYFSIGVDASIAHRFHUMREK <mark>HPEKFNSR</mark> MKNKHWYFEFGTSETFAATCKKLHBHI ***********************************	570 637 633
DGKaA P51556 512-693 DGKbA P49621 579-759	TVEICGKLLDLSDLSLEGIAVLNIPSMHGGSNLWGDTKRPHGDTCGINQALGSVAKIITD EIECDGVQIDLINISLQGIAILNIPSMHGGSNLWGESKKRRSHRR-IEKKGSDKRPTLTD ELECPOVUZDELNIELGGIALNIPGWCGZNLWGEYKKNRANIG	630 696
Davga   P49020   575-749	:* * :** :: *:************************	000
DGKaA P51556 512-693	PDILKTCVPDMSDKRLEVVGIEGVIEMGQIYTRLKSAGHRLAKCSEITFQTTKTLPMQVD	690
DGKbA P49621 579-759	AKELKFASQDLSDQLLEVVGLEGAMEMGQIYTGLKSAGRRLAQCSSVVIRTSKSLPMQID	756
DGKgA P49620 575-749	PKELKCCVQDLSDQLLEVVGLEGAMEMGQIYTGLKSAGRRLAQCSSVTIRTKKLLPMQVD ** *:**: *****************************	746
DGKaA   P51556   512-693	GEP 693	
DGKbA P49621 579-759	GEP 759	
DGKgA P49620 575-749	GEP 749 ***	
# Percent Identity	Matrix - created by Clustal2.1	
1: DGKaA P51556	512-693 100.00 63.54 66.86	
2: DGKbA P49621	579-759 63.54 100.00 81.14	
3: DGKgA P49620	575-749 66.86 81.14 100.00	

Supplementary Figure 12. Sequence alignment of type 1 DGK domains containing probe-modified active site lysines detected by activity-based profiling with ATP acyl phosphates. Multiple protein sequence alignment of the type 1 rat DGK isoforms (DGKa, DGKb, DGKg) using Clustal Omega highlighting the sequence similarity within the conserved "archetypal" DGK superfamily domains; C1A (green), C1B (blue), catalytic (C, orange), and accessory (A, orange) domains. Regions highlighted in yellow indicate detected tryptic peptides containing probe-modified sites (lysine site of binding highlighted in red) while regions in purple indicate predicted tryptic peptide sequences that were not identified but still contain a conserved lysine residue that is available for probe modification.



Supplementary Figure 13. Doxycycline-inducible knockdown of DGK $\alpha$  in non-small cell lung cancer A549 cells. Western blot displaying shRNA-mediated knockdown (KD) of DGK $\alpha$  in A549 cells following 0.2 µg/mL treatment of doxycycline for 48 hours. A DGK $\alpha$ -specific antibody was used to detect levels of endogenous DGK $\alpha$  (*n*=5 biological samples). Full blot image is shown in Supplementary Fig. 28. Data shown are representative of two experiments (*n*=2 biologically independent samples).



A549 doxycycline DGK $\alpha$  knockdown DAG Metabolism

Supplementary Figure 14. Accumulation of cellular DAGs following shRNA-mediated knockdown of endogenous DGKa in A549 cells. Knockdown of endogenous DGKa in A549 cells (0.2 µg/mL doxycycline, 48 hours, n=4 biological samples) resulted in accumulation of DAG lipids with the indicated fatty acyl composition. Cellular reductions in these same DAG species in gain of DGKa function studies (Supplementary Table 3) support our metabolomics approach for mapping authentic DGK substrates in live cells. Significance of lipid alterations was determined using a Benjamini-Hochberg correction following a two-sided binomial test (\*Q < 0.05, \*\*Q < 0.01). Data shown represents mean  $\pm$  s.e.m. Data shown are representative of two experiments (n=2 biologically independent experiments).



Supplementary Figure 15. Expression levels of recombinant DGK $\alpha$  wild-type and lysine mutant proteins are comparable. Western blot showing equivalent expression of wild-type (WT) and lysine-toalanine mutants of rat DGK $\alpha$ . Lysines selected for mutation are those identified by chemical proteomic analyses with ATP acyl phosphates shown in Fig. 3. Recombinant WT and mutant DGK $\alpha$  expression levels were detected and compared by western blot analysis with an anti-FLAG antibody (*n*=3 biological samples). Full blot image is shown in Supplementary Fig. 29. Data shown are representative of two experiments (*n*=2 biologically independent experiments).



Supplementary Figure 16. Treatment with small molecule inhibitors does not affect expression levels of recombinant DGKa in cells. Western blot showing equivalent expression of recombinant rat DGKa in overexpressing HEK293T cells treated with DMSO vehicle, ritanserin (Rit), or ketanserin (Ket, 25  $\mu$ M compounds, 1 hour, *n*=2 biological samples). Soluble and membrane fractions are shown. Detection was achieved using an anti-FLAG antibody. Full blot image is shown in Supplementary Fig. 30. Data shown are representative of two experiments (*n*=2 biologically independent experiments).

DGKa	MAKDKGLISPEDFAQLQKYIDYSTKSVSDVLKVFEMNKYCQGDEIGY	47
DGKb	MTNQEKWAHLSPSEFSOLOKYAEYSTKKLKDVLEEFHGNGVLAKYNPEGKODILNOTIDF	60
DGKa		52
Dong	· · · · · · · · · · · · · · · · · · ·	02
DOW		0.0
DGKa	LGFEQFLKMYLEVEEVPHHLCWTLFWSFHSSQDLD	82
DGKb	EGFKLFMKTFLEAE-LPDDFTAHLFMSFSNKFPHSSPNVKSKPALLSGGLR	110
DGKg	DVFKLFMRAYLEVD-LPQPLSTNLFLAFSQKPRQETPDHPKEGASSSEPNVSDSNAESTA	111
	*: *:: :**. : ** :*	
DGKa	EETESKANVICLSDVYCYFTLLEGG	107
DGKb	MNKGAITPPRSSPANTCFPEVIHLKDIVCYLSLLERG	147
DGKa	KADAACAPDTESKPIKTOVPSEELEAAAPWGEPNAPASSSDAPIVYLKDVVCYLSIMETG	171
Dong	·· * *· **··** *	- / -
DOV-		1 (7
DGKa	SPEDRIEFIERLIDMDRIGIEDSIEVERIILQMMRVAEILDWDVSELRPILQEMMREMDR	107
DGKD	RPEDKLEFMFRLYDTDGNGFLDSSELENIIGQMMHVAEYLEWDVTELNPILHEMMEEIDY	207
DGKg	RPQDKLEFMFRLYDSDENELLDQAELDQIVSQMLHVAQYLEWDPTELRPILKEMLQGMDY	231
	* * * * * * * * * * * * * * * * * * * *	
	Begin Domain Transfer C1A Domain	
DGKa	DGSGCVSLAEWVRAGATTVPLLVLLGIDMT-MKDDG <mark>HHIWRPKRFSRPVYCNLCEL-SIG</mark>	225
DGKb	DRDGTVSLEEWIQGGMTTIPLLVLLGLENN-VKDDGQHVWRLKHFNKPAYCNLCLNMLIG	266
DGKa	NKDGEVSDEEWVSGGMTTTEDIVLLGMDDSASKGDGRHAWTLKHFKKPTYCNFCHIMLMG	291
-	• * *** **• * **•****** * * **•* * *** **	
	C1B Domain	
DCKa		285
DGKa		200
DGKD	VGRQGLCCSFCKYTVHERCAR-APPSCIKTYVSKKNTDVMHHYWVEGNCP-TKCDKCHK	324
DGKg	VRKQGLCCIICKIAVHQRCVSNSIPGCVKTISKAKRSGEVM <mark>QHAWVEGNSS-VKCDRCHK</mark>	350
	· **** * *** **··*. · * · ** *··· * * ***.* · ***	
DGKa	KIRTYHSLTGLHCVWCHLEIHDDCLQAVGPECDCGLLRDHILPPCSIYPRVLVSGQECKQ	345
DGKb	TVKCYQGLTGLHCVWCQTTLHNKCASHLKPECDCGPLKDHILPPTTICPVVLTMPTAGTS	384
DGKq	SIKCYOSVTARHCVWCRMTFHRKCELSTACDGGELKDHILLPTSIYPVTRDROAGK	406
	• * • * ***** • * * • ** * * * *	
	End Domain Transfer	-
DGKa	TSLCTPEAFRIEPVSNUTPUTPUTPUTPUTPUTPUTPUTPUTPUTPUTPUTPUTPU	378
DGKb	VPEEROSTAKKEKGSSOOPNKVTDKNKMORANSVTMDGOGLOITPI <b>PCTHPLIVEVNPKS</b>	444
DGKa		440
Dong		110
DOV-		107
DGKa	GGRQGQSVLWRFQIILNPRQVFNLK-DGPEPGLRFFRDVPQFRVLVCGGDGIVGWILEII	437
DGKb	GGKQGERIYRKFQYLLNPRQVYSLSGNGPMPGLHFFRDVPDFRVLACGGDGTVGWILDCI	504
DGKg	GGRQGERILQKFHYLLNPKQVFNLDKGGPTPGLNFFQDTPDFRVLACGGDGTVGWILDCI	500
	** *** * ** ** *** *** ** ** ** *** *** *** ****	
DGKa	DKANFPIVPPVAVLPLGTGNDLARCLRWGRGYEGENLRKILKDIEISKVVYLDRWLLEVI	497
DGKb	EKANVVKHPPVAILPLGTGNDLARCLRWGGGYEGENLMKILKDIESSTEIMLDRWKFEVT	564
DGKa	DKANFTKHPPVAVLPLGTGNDLARCLRWGGGYEGGSLTKILKEIEOSPLVMLDRWYLEVM	560
- 5	•*** *********************************	
DCVA	DOONCEVED DUDGOT THINKEST CUDA CTA UDEUT MDEVVDEVENCOMVNIVI MVI E DA BCE	667
DGKa	PQQNGERSDPVPSQTINNIFSIGVDASIARRFILEMRERIPERFNSRMRNRLWILEFAISE	557
DGKD	PNDKDEKGDPVPYSIINNYFSIGVDASIAHRFHIMREKHPEKFNSRMKNKFWYFEFGTSE	624
DGKg	PREEVENGDQVPYNIMNNYFSIGVDASIAHRFHVMREKHPEKFNSRMKNKLWYFEFGTSE	620
	* • • * • * * * * • * * * * * * * * * *	
DGKa	SIFSTCKKLEESVTVEICGKLLDLSDLSLEGIAVLNIPSMHGGSNLWGDTKRPHGDTCGI	617
DGKb	TFSATCKKLHESVEIECDGVOIDLINISLOGIAILNIPSMHGGSNLWGESKKKRSHRR-I	683
DGKa	TFAATCKKLHDHIELECDGVEVDLSNIFLEGIAILNIPSMYGGTNLWGETKKNRAVIR-E	679
5	•• •***** • • •* * •** •• *************	
DCKA		677
DGNd	MANGORN DEFINITION CONTROL OF A MANAGEMENT OF A CONTROL AND A	0//
DGKD	ERRGSDREPTLTDAKELKFASQDLSDQLLEVVGLEGAMEMGQ1YTGLKSAGRRLAQCSSV	/43
DGKg	SKKSVTDPKELKCCVQDLSDQLLEVVGLEGAMEMGQIYTGLKSAGRRLAQCSSV	733
	•** ** ** * **** *********************	
DGKa	TFQTTKTLPMQVDGEPWMQAPCTIKITHKNQMPMLMGPAPSSSNFFGFWS	727
DGKb	VIRTSKSLPMQIDGEPWMQTPCTIKITHKNQAPMLMGPPPKTGLFCSLIKRTRNRSKE	801
DGKq	TIRTKKLLPMQVDGEPWMQPPCMIKITHKNOAPMMMGPPOKSSFFSLRR-KSRSKD	788
2	* * ********************************	

Supplementary Figure 17. Sequence alignment of type 1 DGK isoforms. Multiple protein sequence alignment (Clustal Omega) of rat type 1 DGKs to identify homologous regions for C1 domain swaps by protein engineering. Highlighted amino acid sequences denote key locations used for generation of the C1 chimera proteins; black = region enclosing the C1 domain swap, red = DGK $\alpha$  C1 sequences, blue = DGK $\beta$  C1 sequences, and green = DGK $\gamma$  C1 protein sequences.



Supplementary Figure 18. Expression of type 1 recombinant DGK chimeras. Western blot analysis showing expression of recombinant rat DGK wild-type (WT) and C1 domain chimeras in proteomes from overexpressing HEK293T cells (n=3 biological samples). Detection was achieved using an anti-FLAG antibody. Full blot image is shown in Supplementary Fig. 31. Data shown are representative of four experiments (n=4 biologically independent experiments).



Supplementary Figure 19. Recombinant DGK chimeras are catalytically active. Recombinant DGK chimeras are catalytically active as judged by a liposomal substrate assay against both C18:1\_C18:1 (n=3 biological samples) and C18:0\_C18:0 (n=2 biological samples) DAG substrate. Liposomes used for substrate assays contained the following composition: 70% DOPC, 20% DOPS, and 10% DAG. Recombinant DGK overexpressed-HEK293T proteomes were used for substrate assays. Data shown represent mean  $\pm$  s.e.m. Displayed activity (nmol/min/mg total protein) includes subtraction of mock background levels. Data shown are representative of one experiment (n=1 biologically independent experiment).



Supplementary Figure 20. Assigning DAG substrate specificity to type 1 rat DGKs. Heat map displaying cellular alterations in the DAG lipidome ( $log_2$  fold change) in recombinant rat type 1 DGK overexpressed- compared with mock non-transfected-HEK293T cells (n=6 biological samples). Data shown are representative of two experiments (n=2 biologically independent experiments).



Supplementary Figure 21. Immunofluorescence analysis of recombinant DGKa and chimeras overexpressed in HEK293T cells. Images were acquired using a Zeiss 780 NLO Confocal microscope. Membrane staining was accomplished using a wheat germ agglutinin (WGA) conjugated to an Alexa 350 nm fluorophore. Expression of recombinant DGKs (WT and chimeras) was detected using an anti-FLAG antibody. Immunofluorescence did not reveal a clear correlation between subcellular localization of DGK chimera and the WT isoform from which C1 domains were derived. Scale bars are set at 20  $\mu$ m. Data shown are representative of two experiments (*n*=2 biologically independent experiments).



Supplementary Figure 22. Immunofluorescence analysis of recombinant DGK $\beta$  and chimera overexpressed in HEK293T cells. Experimental conditions for data shown are described in Supplementary Fig. 21. Data shown are representative of two experiments (*n*=2 biologically independent experiments).



Supplementary Figure 23. Immunofluorescence analysis of recombinant DGK $\gamma$  and chimera overexpressed in HEK293T cells. Experimental conditions for data shown are described in Supplementary Fig. 21. Data shown are representative of two experiments (n=2 biologically independent experiments).



Supplementary Figure 24. Full images of blots related to Fig. 1d.

kDa	12hr 24hr 48hr	kDa	~2 <sup>h1</sup> 2 <sup>A</sup> <sup>N1</sup> 48 <sup>h1</sup>	kDa	12h 24h 48h	kDa	12hr 24hr 48hr	kDa	12hr 24hr 48hr	kDa	12h 24h 48h
250 <b>-</b>		250 <b>-</b>		250 <b>-</b>	5 5 B	250 <b>-</b>		250 <b>-</b>		250 <b>-</b>	
150 <b>-</b>		150-		150 <b>-</b>		150 <b>-</b>		150 <b>-</b>		150 <b>-</b>	
100 <b>–</b>	terrer been terrer	100 <b>-</b>	100 E.S. 800	100-		100 <b>-</b>		100-		100-	
75 <b>-</b>		75 <b>-</b>		75 <b>-</b>		75 <b>-</b>		75 <b>-</b>		75-	
50 <b>-</b>		50 <b>-</b>		50 <b>-</b>		50 <b>-</b>		50 <b>-</b>		50 <b>-</b>	
37 <b>-</b>		37 <b>-</b>		37-		37 <b>-</b>		37 <b>-</b>		37 <b>-</b>	
25 <b>-</b>		25 <b>-</b>		25 <b>-</b>		25 <b>-</b>		25 <b>-</b>		25 <b>-</b>	
20 <b>-</b>		20 <b>-</b>		20-		20 <b>–</b>		20 <b>-</b>		20 <b>-</b>	
15 <b>-</b>		15 <b>-</b>		15-		15 <b>-</b>		15 <b>-</b>		15 <b>-</b>	
10 <b>-</b>		10-		10-		10-		10-		10 <b>-</b>	
	Mock		DGKα		DGKĸ		DGKε		DGKζ2		DGK0

Supplementary Figure 25. Full images of blots related to Supplementary Fig. 3.



Supplementary Figure 26. Full images of blots related to Supplementary Fig. 4.







Supplementary Figure 27. Full images of blots related to Supplementary Fig. 7.

kDa	Scramble	A549 DGK $\alpha$ KD + Doxycycline				
250 <b>-</b>	BBBBB					
150 <b>-</b>						
100 <b>-</b>						
75 <b>-</b>						
	trend many party party dates					
50 <b>-</b>						
37 <b>-</b>						
25 <b>-</b>		terri and store water water				
20 <b>-</b>		Transfer over and the line				
15 <b>-</b>						
10 <b>-</b>	E TOPT	201				

Supplementary Figure 28. Full images of blots related to Supplementary Fig. 13.



Supplementary Figure 29. Full images of blots related to Supplementary Fig. 15.



Soluble



Supplementary Figure 30. Full images of blots related to Supplementary Fig. 16.

kDa	Mock	$DGK\alphaWT$	DGKβ WT	DGK <sub>Y</sub> WT	DGKαC1β chimera	DGKαC1γ chimera	DGKβC1α chimera	DGKγC1α chimera
250 <b>-</b>								
150 <b>-</b>								
100-								
75 <b>-</b>		===						
50 <b>-</b>								
37 <b>-</b>								
25-								
20-								
15 <b>-</b>								
10 <b>-</b>								

Supplementary Figure 31. Full images of blots related to Supplementary Fig. 18.

## SUPPLEMENTARY DATASETS

## **Supplementary Dataset 1.**

A) Results from LipidSearch analysis of both positive and negative mode ddMS2 data from DGK overexpressed HEK293T lipidomes. Job results for identified lipid species are filtered as outlined in Supplementary Figure 5. Data displayed are used to generate Fig. 1b.

B) Abundances of identified DAG species from DGK $\epsilon$  overexpressed HEK293T lipidomes following a targeted PRM analysis identifying the NH<sub>4</sub><sup>+</sup> adduct. Normalization is accomplished using the detected SAG-d8 internal standard and protein concentration. Data displayed is used to generate Fig. 1d.

C) Log<sub>2</sub> fold changes of DAG abundances from various DGK isoforms overexpressed in HEK293T cells. All DGK isoforms are the human variant. Data displayed is used to generate Fig. 2a and b and Supplementary Fig. 8, 9 and 11.

D) SILAC ratios and modified peptides of soluble proteins from DMSO (light)/ATP (heavy) treatments of HEK293T cells overexpressed with type 1 rat DGK isoforms with the ATP acyl phosphate probe. Data displayed is used to generate Fig. 3.

E) Abundances of identified DAG species from type 1 human DGK isoform overexpressed HEK293T lipidomes following a targeted PRM analysis identifying the  $NH_4^+$  adduct. Data displayed is used to generate Fig. 4a.

F) Abundances of identified DAG species from A549 lipidomes following doxycycline-induced shRNA knockdown of DGK $\alpha$ . Data displayed is used to generate Fig. 4b.

G) Abundances of identified DAG species from rat DGK $\alpha$  WT and lysine mutant overexpressed HEK293T lipidomes following a targeted PRM analysis identifying the NH<sub>4</sub><sup>+</sup> adduct. Data displayed is used to generate Fig. 4c.

H) Abundances of identified DAG species from rat DGKα WT overexpressed HEK293T lipidomes treated *in situ* with ritanserin and ketanserin. Data displayed is used to generate Fig. 4d.

I) Abundances of identified DAG species from type 1 rat DGK WT and C1 chimera overexpressed HEK293T lipidomes following a targeted PRM analysis identifying the  $NH_4^+$  adduct. Data displayed is used to generate Fig. 5.

J) Log<sub>2</sub> fold changes of PA abundances from various DGK isoforms overexpressed in HEK293T cells. All DGK isoforms are the human variant. Data displayed is used to generate Supplementary Fig. 10 and 11.

K) Phosphorylation activity studies of type 1 DGK WT and chimera isoforms overexpressed in HEK293T soluble proteomes. Formation of radiolabeled [ $\gamma^{32}$ -P] PA product is used to determine *in vitro* DGK activity from liposome substrates. Data displayed are used to generate Supplementary Fig. 19.

L) Log<sub>2</sub> fold changes of DAG abundances from type 1 DGK isoforms overexpressed in HEK293T cells. All DGK isoforms are the rat variant. Data displayed are used to generate Supplementary Fig. 20.